# Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

> **NCT00061646** · PHASE2 · TERMINATED · sponsor: **Abbott** · enrollment: 25 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** ABT-510/Thrombospondin-1 mimetic
- **DRUG:** Carboplatin/Taxol

## Key facts

- **NCT ID:** NCT00061646
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease progression.
- **Last updated:** 2007-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061646, "Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00061646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*